Integrated Biopharma

Integrated Biopharma EBIT per Employee

The EBIT per Employee of Integrated Biopharma (INBP) as of Oct 9, 2026 is 13,202.61 USD. In the previous year, EBIT per Employee was 1,640.52 USD — a change of 704.78% (higher).

EBIT per Employee

13,202.61USD

YoY

704.78%

Last updated:

EBIT per Employee of Integrated Biopharma is 2025 13,202.61 USD. EBIT per Employee of Integrated Biopharma was 2024 1,640.52 USD. It decreases by 704.78% higher compared to the previous year.

The Integrated Biopharma EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
11,071.90 USD
Jan 1, 2019
17,673.20 USD
Jan 1, 2020
21,300.65 USD
Jan 1, 2021
37,803.92 USD
Jan 1, 2022
17,941.18 USD
Jan 1, 2023
784.31 USD
Jan 1, 2024
1,640.52 USD
Jan 1, 2025
13,202.61 USD
The Integrated Biopharma EBIT per Employee history
YEAREBIT per EmployeeYoY
13,202.61USD+704.78%
1,640.52USD+109.17%
784.31USD-95.63%
17,941.18USD-52.54%
37,803.92USD+77.48%
21,300.65USD+20.53%
17,673.20USD+59.62%
11,071.90USD-46.85%
20,830.07USD+50.76%
13,816.99USD+126.58%
6,098.04USD-30.99%
8,836.60USD—
Access this data via the Eulerpool API

Integrated Biopharma Stock analysis

What does Integrated Biopharma do? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrated Biopharma stock

EBIT per Employee of Integrated Biopharma is 13,202.61 USD in 2025.

EBIT per Employee of Integrated Biopharma changed from 1,640.52 USD to 13,202.61 USD, representing a 704.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Integrated Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Integrated Biopharma historically and in real time.

Access this data via the Eulerpool API

Workforce — Integrated Biopharma

All Key Metrics — Integrated Biopharma